Topics:

Weak Provenge sales send Dendreon shares tumbling

Tools

Dendreon ($DNDN) had its biggest share price fall in 21 months last week after sales of prostate cancer vaccine Provenge fell short of expectations. The miss means Dendreon now expects to fail to achieve its modest goal of growing sales this year. Article

Filed Under

Comments